Wednesday’s Trading Day
| 6.30 | -0.09 / -1.41% |
Data as of Jun 19 | Day’s Change | |
| 6.37 | +0.07 / +1.11% |
| Volume: 5.5K |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $401.2M |
Company Description
PROLOR Biotech, Inc. is engaged in the development of proprietary versions of already approved therapeutic proteins. Its products under development include Human Growth Hormone (hGH), Glucagon dual receptor agonist (GLP-1), Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon ß and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded on August 22, 2003 and is headquartered in Nes Ziona, Israel.
Employees

Shareholders
| Other institutional | 9.45% |
| Individual stakeholders | 26.48% |
| Mutual fund holders | 2.44% |
Top Executives
| Abraham Havron, PhD | Chief Executive Officer & Director |
| Shai A. Novik, MBA | President & Director |
| Eyal Fima, PhD, MBA | Chief Operating Officer |
| Steve Schaeffer | Chief Financial Officer |
| Fuad Fares, DSc | Director & Chief Scientific Officer |